Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- According to data published by Precedence Research, the AI-driven bioengineering sector features companies like Ginkgo Bioworks ($478M revenue), Generate Biomedicines ($700M funding), and Recursion Pharmaceuticals ($261M revenue), designing millions of proteins and strains daily, screening over 15 billion compounds via AI, and training models on hundreds of millions of protein structures. Government programs in the USA, EU, UK, China, and Japan provide multi-billion-dollar funding, accelerating AI-enabled bioengineering innovation.
The AI-driven bioengineering market is transforming life sciences with high-throughput protein, strain, and compound design platforms, supported by hundreds of millions to billions in global funding, data published by Precedence Research.
Invest in Our Premium Strategic Solution: https://www.precedenceresearch.com/request-consultation/42
Key Company Insights
| Company | Country | Real Revenue / Funding | HARD NUMBERS (Platform-Specific) | Platform Focus |
| Ginkgo Bioworks | USA | $478.4M (2023) | 124 active programs; 50,000+ strain designs/year; Foundry >100 bioreactors | AI-driven strain engineering |
| Recursion Pharmaceuticals | USA | $261M (2023) | >23 PB biological image data; 50M+ experiments/year | AI biology + phenomics |
| Insilico Medicine | USA / HK | $400M+ funding | 30+ AI-generated drug candidates; 10 in clinical stage | Generative biology |
| Exscientia | UK | $300M+ revenue | >20 AI-designed candidates; 4 in clinical trials | AI-designed therapeutics |
| Deep Genomics | Canada | $180M funding | AI models trained on millions of RNA splicing variants | RNA engineering |
| Generate Biomedicines | USA | $700M funding | Millions of protein sequences/day | Generative protein design |
| Atomwise | USA | $174M funding | Screened 15+ billion compounds via AI | Structure-based AI |
| Schrödinger | USA | $219M revenue (2023) | Physics-ML hybrid models; >2,000 enterprise customers | Molecular simulation |
| Benchling | USA | $100M+ ARR | 200k+ scientists; 1,200+ companies | Cloud bioengineering OS |
| Zymergen | USA | $630M funding (pre-acquisition) | AI-guided strain optimization; thousands of variants/run | ML-guided materials bio |
| Arzeda | USA | $110M funding | Enzyme yield improvements 5–10× | Computational enzyme design |
| Absci | USA | $74M revenue (2023) | End-to-end AI-to-wet-lab protein pipeline | AI biologics |
| Owkin | France / USA | $304M funding | Federated learning across 100+ hospitals | AI + biomedical data |
| Valo Health | USA | $190M funding | Human-centric AI platform; multi-omics scale | AI bioengineering |
| Google DeepMind | UK | Alphabet funded | AlphaFold trained on 200M+ proteins | Protein structure prediction |
Platform Throughput & Compute
| Platform | Real Throughput / Scale |
| Ginkgo Bioworks | 50k+ strain designs/year |
| Recursion Pharmaceuticals | 50M+ experiments/year |
| Generate Biomedicines | Millions of protein designs/day |
| Atomwise | 15B compounds screened |
| DeepMind AlphaFold | 200M protein structures released |
| Benchling | 200k+ active scientific users |
Government & Public Sector Funding
| Country | Agency | Program | REAL FUNDING |
| USA | DARPA | Living Foundries | $300M+ |
| USA | NIH | AI-enabled biology grants | $1.4B (FY2023) |
| USA | DOE | BioFoundry Network | $580M cumulative |
| EU | European Commission | Horizon Europe AI + Bio | €95.5B program |
| UK | UKRI | AI for Life Sciences | £1B+ allocated |
| China | MOST | AI + Biotechnology | ¥10B+ public funding |
| Japan | METI | Bio-Digital Transformation | ¥100B+ strategy |
Market Insights
- High-Throughput AI Platforms: Companies design millions of proteins and microbial strains per day, screen billions of compounds, and model hundreds of millions of protein structures.
- Acceleration of Discovery: AI reduces years of experimental iteration into days of compute, enabling rapid drug candidate identification and biomaterial optimization.
- Government Investment: Hundreds of millions to billions in public funding worldwide drive platform access, research partnerships, and commercialization.
- Revenue Models: Most revenue today stems from platform access, collaborations, and partnerships rather than end products.
How Precedence Research Can Help
Precedence Research delivers actionable insights and quantitative intelligence for AI-driven bioengineering:
- Company Financial & Platform Data: Revenue, funding, AI throughput, and active program counts.
- Government & Public Funding: DARPA, NIH, DOE, Horizon Europe, UKRI, METI, and MOST allocations.
- Market Forecasting & Scenario Modeling: Platform adoption, AI throughput growth, and commercialization impact.
- Strategic Reports: Tailored insights for investment, R&D prioritization, and partnership strategies.
Contact Us:
Email: sales@precedenceresearch.com
USA: +1 8044 419344 | APAC: +61 4859 81310 / +91 87933 22019 | Europe: +44 7383 092 044
Precedence Research – Transforming AI and Bioengineering Data into Strategic Decisions
